The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behavior disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 16, Issue 6, 2006, Pages 725-735

  Günther, Thomas ^a   Herpertz Dahlmann, Beate ^a   Jolles, Jellemer ^b   Konrad, Kerstin ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMPHETAMINE; METHYLPHENIDATE; RISPERIDONE;

ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; COGNITION; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DISRUPTIVE BEHAVIOR; FEMALE; HUMAN; IMPULSIVENESS; INTELLIGENCE QUOTIENT; IOWA CONNERS SCALE; MALE; MONOTHERAPY; NEUROPSYCHOLOGICAL TEST; PRESCHOOL CHILD; RATING SCALE; SCHOOL CHILD; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 33846622320     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.16.725     Document Type: Article

References (68)

1. Allain H, Tessier C, Bentué Ferrer D, Tarral A, Le Brenton S, Gandon JM, Bouhours P: Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers. Psychopharmacology (Berl). 165:419-429, 2002.
2. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL: Risperidone disruptive behavior study group: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346, 2002.
3. Aman MG, Binder C, Turgay A: Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 14:243-254, 2004.
4. Aman M, Buitelaar J, De Smedt G, Wapenaar R, Binder C: Pharmacotherapy of disruptive behavior and item changes on a standardized rating scale: Pooled analysis of risperidone effects in children with subaverage IQ. J Child Adolesc Psychopharmacol. 15:220-232, 2005a.
5. Aman MG, Arnold E, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken JT, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, Swiezy NB, Ritz L, Koenig K, McGough J, Ghuman J, Lindsay RL: Acute long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol. 15:869-884, 2005b.
6. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, DC, American Psychiatric Association, 1994.
7. Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J: Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry 36:694-700, 1997.
8. Arnold LE, Vitello B, McDougle C, Scahill L, Shah B, Gonzalez NM, Chuang S, Davies M, Hollway J, Aman MG, Cronin P, Koenig K, Kohn AE, McMahon DJ, Tierney E: Parent-defined target symptoms respond to risperidone in RUPP Autism Study: Customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 42:1443-1450, 2003.
9. Barch DM, Sheline YI, Csernansky JG, Snyder AZ: Working memory and prefrontal cortex dysfunction: Specificity to schizophrenia compared with major depression. Biol Psychiatry 53:376-384, 2003.
10. Barnard L, Young AH, Pearson J, Geddes J, O'Brien G: A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol (Oxf) 16:93-101, 2002.
11. Barrett SL, Bell R, Watson D, King DJ: Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers. J Psychopharmacol (Oxf) 18:156-172, 2004.
12. Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA: Risperidone versus pimozide in Tourettes's disorder: A comparative double-bind parallel group study. J Clin Psychiatry 62:50-56, 2001.
13. Buitelaar JK: Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol 10:19-26, 2000.
14. Buitelaar JK, van der Gaag RJ, Cohen Kettenis P, Melman CT: A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62:239-248, 2001.
15. Campbell M, Gonzalez NM, Silva RR: The pharmacological treatment of conduct disorders and rage outbursts. Psychiatr Clin N Am 15:69-85, 1992.
16. Cesena M, Gonzalez Heydrich J, Szigethy E, Kohlenberg TM, DeMaso DR: A case series of eight aggressive young children treated with risperidone. J Child Adolesc Psychopharmacol 12:337-345, 2002.
17. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT: Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 14:372-394, 2004.
18. Collett BR, Ohan JL, Myers KM: Ten-Year Review of Rating Scales. V: Scales asessing attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 42:1015-1037, 2003.
19. Correia Filho AG, Bodanese R, Silva TL, Alvares JP, Aman M, Rohde LA: Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. J Am Acad Child Adolesc Psychiatry 44:748-755, 2005.
20. de Sonneville LMJ: ANT 2.1-Amsterdam Neuropsychological Tasks. Amstelveen, Sonar, 2000.
21. Eapen V, Gururaj AK: Risperidone treatment in 12 children with developmental disorders and attention-deficit/hyperactivity disorder. Prim Care Companion J Clin Psychiatry. 7:221-224, 2005.
22. Fimm B, Zimmermann P: Testbatterie zur Aufmerksamkeitsüberprü fung (TAP), Version 1.6. Herzogenrath, Psytest, 2001.
23. Findling RL, McNamara NK: Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 65 (Suppl 6):30-44, 2004.
24. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon ERN, Blumer JL: A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509-516, 2000.
25. Frazier JA, Meyer MC, Biederman J, Wozniak J, Wilens TE, Spencer TJ, Kim GS, Shapiro S: Risperidone treatment for juvenile bipolar disorder: A Retrospective Chart Review. J Am Acad Child Adolesc Psychiatry 38:960-965, 1999.
26. Gaffney GR, Perry PJ, Lund BC, Bever Stille KA, Arndt S, Kuperman S: Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 41:330-336, 2002.
27. Gilbert DL, Batterson R, Sethuraman G, Sallee FR: Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 43:206-214, 2004.
28. Goodwin CJ: Research in Psychology-Methods and Design. John Wiley & Sons, Inc. (New York), 1998.
29. Grcevich SJ, Findling RL, Rowane WA, Friedman L, Schulz SC: Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. J Child Adolesc Psychopharmacol 6:251-257, 1996.
30. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S, American Academy of Child and Adolescent Psychiatry: Practice parameters for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41:26S-49S, 2002.
31. Halperin JM, O'Brien JD, Newcorn JH, Healey JM, Pascualvaca DM, Wolf LE, Young JG: Validation of hyperactive, aggressive, and mixed hyperactive/ aggressive childhood disorders: A research note. J Child Psychol Psychiatry 31:455-459, 1990.
32. Hellings JA, Zarcone JR, Valdovinos MG, Reese RM, Gaughan E, Schroeder SR: Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J Child Adolesc Psychopharmacol 15:885-892, 2005.
33. Hill J: Biological, psychological and social processes in the conduct disorders. J Child Psychol Psychiatry 43:133-164, 2002.
34. Huang Pollock CL, Nigg JT: Searching for the attention deficit in attention deficit hyperactivity disorder: The case of visuospatial orienting. Clin Psychol Rev 23:801-830, 2003.
35. Kaplan SL, Simms RM, Busner J: Prescribing practices of outpatient child psychiatrists. J Am Acad Child Adolesc Psychiatry 32:577-581, 1994.
36. Keefe RS, Silva SG, Perkins DO, Lieberman JA: The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr Bull 25:201-222, 1999.
37. Kewley GDFRCP: Risperidone in comorbid ADHD and ODD/CD. J Am Acad Child Adolesc Psychiatry 38:1327-1328, 1999.
38. King B, Zwi K, Nunn K, Longworth J, Dossetor D: Use of risperidone in a paediatric population: An opservational study. J Paediatr Child Health 39:523-527, 2003.
39. Konrad K, Günther T, Hanisch C, Herpertz-Dahlmann B: Differential effects of methylphenidate on attentional functions in children with attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 43:191-198, 2004.
40. Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, Findling RL, Fisman S, Greenhill LL, Huss M, Kusumakar V, Pine D, Taylor E, Tyano S: International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): Clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 14:11-28, 2004.
41. Leysen JE, Janssen PMF, Gommeren W, Wynants J, Pauwels PJ, Janssen PAJ: In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotic risperidone and ocaperidone. Mol Pharmacol 41:494-508, 1992.
42. Liu SK, Chen WJ, Chang CJ, Lin HN: Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: A trial of risperidone versus haloperidol. Neuropsychopharmacology 22:311-319, 2000.
43. Lynam DR: The early identification of chronic offenders: Who is the fledgling psychopath? Psychol Bull 120:209-234, 1996.
44. McClellan JM, Werry JS: Evidence-based treatments in child and adolescent psychiatry: An inventory. J Am Acad Child Adolesc Psychiatry 42:1388-1400, 2003.
45. McConville BJ, Sorter MT: Treatment challenges and safety considerations for antpsychotic use in children and adolescents with psychoses. J Clin Psychiatry 65:S20-S29, 2004.
46. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D, Research Units on Pediatric Psychopharmacology Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321, 2002.
47. Moore H, Kleining G: Das soziale Selbstbild der Gesellschaftsschichten in Deutschland. Kölner Zeitschrift für Soziologie und Sozialpsychologie 20:86-119, 1968.
48. Morant A, Mullas F, Hernandez S, Rosello B: Pharmacological treatment with risperidone in children with behavior disorders. Rev Neurol 33:1-15, 2001.
49. Nigg JT: Response inhibition and disruptive behaviors-Toward a multiprocess conception of etiological heterogeneity for ADHD combined type and conduct disorder early-onset type. Ann NY Acad Sci 1008:170-182, 2003.
50. Oosterlaan J, Sergeant JA: Response inhibition and response re-engagement in attention-deficit/hyperactivity disorder, disruptive, anxious and normal children. Behav Brain Res 94:33-43, 1998.
51. Oosterlaan J, Logan GD, Sergeant JA: Response Inhibition in AD/HD, CD, comorbid AD/HD+CD, anxious, and control children: A meta-analysis of studies with the stop task. J Child Psychol Psychiatry 39:411-425, 1998.
52. Pelham WE, Milich R, Murphy DA, Murphy H: Normative data on the IOWA Conners Teacher Rating Scale. J Clin Child Psychol 18:259-262, 1989.
53. Pelham WE, Wheeler T, Chronis A: Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Psychol 27:190-205, 1998.
54. Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS: A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130-1135, 2003.
55. Scheres A, Oosterlaan J, Swanson J, Morein Zamir S, Meiran N, Schut H, Vlasveld L, Sergeant JA: The effect of methylphenidate of three forms of response inhibition in boys with AD/HD. J Abnorm Child Psychol 31:105-120, 2003.
56. Schreier HA: Risperidone for young children with mood disorders and aggressive behavior. J Child Adolesc Psychopharmacol 8:49-59, 1998.
57. Sergeant JA: Modeling attention-deficit/hyperactivity disorder: A critical appraisal of the cognitive-energetic model. Biol Psychiatry 57:1248-1255, 2005.
58. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F: Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:634-641, 2004.
59. Simeon J, Milin R, Walker S: A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 26:267-275, 2002.
60. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A: The Risperidone Study Group: Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036, 2002.
61. Solanto MV: Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res 130:65-71, 2002.
62. Tabachnick BG, Fidell LS: Using Multivariate Statistics. Allyn & Bacon, New York, 2000.
63. Turgay A: Aggression and disruptive behavior disorders in children and adolescents. Expert Rev Neurotherapeut 4:623-632, 2004.
64. Turgay A: Treatment of comorbidity in conduct disorder with attention-deficit hyperactivity disorder (ADHD). Essential Psychopharmacology 6:277-290, 2005.
65. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders with subaverage IQs. Pediatrics 110:e34, 2002.
66. Unnewehr S, Schneider S, Margraf J: Kinder DIPS-Diagnostisches Interview bei psychischen Störungen im Kindes und Jugendalter. Springer, Heidelberg, 1995.
67. van Goozen SHM, Cohen Kettenis PT, Snoek H, Matthys W, Swaab-Barneveld H, van Engeland H: Executive functioning in children: A comparison of hospitalised ODD and ODD/ADHD children and normal controls. J Child Psychol Psychiatry 45:284-292, 2004.
68. Van Zomeren AH, Brouwer WJ: Theories and concepts of attention. In: Clinical Neuropsychology of Attention. Edited by Van Zomeren AH, Brouwer WJ. Oxford University Press, New York, Oxford, 1994, pp 7-38.